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Abstract
Background: Despite improved survival for the patients with diffuse large B-cell lymphoma (DLBCL), the prognosis after
relapse is poor. The aim was to identify molecular events that contribute to relapse and treatment resistance in DLBCL.
Methods: We analysed 51 prospectively collected pretreatment tumour samples from clinically high risk patients treated in
a Nordic phase II study with dose-dense chemoimmunotherapy and central nervous system prophylaxis with high
resolution array comparative genomic hybridization (aCGH) and gene expression microarrays. Major finding was validated at
the protein level immunohistochemically in a trial specific tissue microarray series of 70, and in an independent validation
series of 146 patients.
Results: We identified 31 genes whose expression changes were strongly associated with copy number aberrations. In
addition, gains of chromosomes 2p15 and 18q12.2 were associated with unfavourable survival. The 2p15 aberration
harboured COMMD1 gene, whose expression had a significant adverse prognostic impact on survival. Immunohistochemical
analysis of COMMD1 expression in two series confirmed the association of COMMD1 expression with poor prognosis.
Conclusion: COMMD1 is a potential novel prognostic factor in DLBCLs. The results highlight the value of integrated
comprehensive analysis to identify prognostic markers and genetic driver events not previously implicated in DLBCL.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
lymphoid neoplasm. It is an aggressive lymphoma entity, and only
50% of patients can be cured with anthracycline-based CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone) or
CHOP-like chemotherapy. However, following the addition of
rituximab or etoposide to CHOP, or the administration of CHOP
dose-densely at two-week intervals (CHOP-14), response rates and
survival have significantly improved [1–5]. Despite these advances,
20–30% of patients experience disease relapses or have primary
refractory disease. Such patients could benefit from alternative
therapies if their clinical outcome could be more accurately
predicted at the time of diagnosis. Therefore, the identification of
biological prognostic factors that could identify high-risk DLBCL
patients is a priority.
Genome-wide molecular profiling has revealed a high degree of
complexity in DLBCL,and significantly accelerated the under-
standing of oncogenic mechanisms in lymphomagenesis [6,7]. On
the basis of gene expression profiling (GEP), DLBCL is classified
into distinct molecular subtypes [8–11]. Three major DLBCL
entities, showing germinal center B-cell (GCB), activated B-cell
(ABC)-like, and primary mediastinal B-cell lymphoma signatures
have been recognized. Many oncogenic mechanisms distinguish
GCB and ABC subtypes. For example, chromosomal transloca-
tions involving BCL2 and the c-REL locus amplification on
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chromosome 2p occur predominantly in the GCB DLBCLs
[10,12]. In contrast, ABC DLBCLs are characterized by
transcriptional overexpression of BCL2 and a constitutive activa-
tion of the NF-kB signaling pathway [10,13]. According to the
gene expression based classification, the patients in the molecular
subgroups also have different outcomes in response to chemo- and
chemoimmunotherapy [9,10].
Over the past few years, progress in molecular genetics and
sequencing technologies has also revealed several previously
unrecognized genetic lesions and pathways that are involved in
DLBCL [14–17]. For example, recurrent mutations inactivating
histone and/or chromatin modifying genes, and genes involved in
immune recognition have been identified. However, despite the
rapidly growing number of genetic aberrations reported in
DLBCL, association of these findings with treatment outcome
remains to be shown.
We have integrated the information from high-resolution gene
copy number and expression microarrays to identify the most
likely ‘‘driver gene’’ candidates associated with DNA copy number
aberrations (CNAs) and poor prognosis in DLBCL. Importantly,
with our cohort of high-risk DLBCL patients treated homo-
genously in a phase II study with dose-dense chemoimmunother-
apy and systemic CNS prophylaxis, we were able to identify a
genomic region harbouring a gene that has a survival effect and
thus is a candidate for a novel molecular marker for poor
prognosis.
Materials and Methods
Ethics Statement
Written informed consent was obtained prior to treatment and
sampling from all patients included in the NLG-LBC-04 study.
Clinical protocol and sampling were approved in the participating
countries at the national level by Regional Committee on Health
Research Ethics in Glostrup, Denmark, the Hospital District of
Helsinki and Uusimaa Regional Committee on Medical Research
Ethics in Finland, Oslo Regional Committee for Medical and
Health Research Ethics in Norway, and Lund Regional Ethics
Committee in Sweden. The trial was registered at ClinicalTrials.-
gov, number NCT01502982. For the retrospectively collected
validation cohort, approval was obtained from the National
Authority for Medicolegal Affairs, Finland and Helsinki University
Central Hospital, Finland.
Patients
The prospectively collected screening (aCGH) and tissue
microarray (TMA) cohorts consisted of DLBCL patients who
were less than 65 years old and had primary high-risk (age-
adjusted International Prognostic Index (aaIPI) score 2–3) disease.
They were treated in the Nordic phase II NLG-LBC-04 protocol
with six courses of R-CHOEP14 (rituximab, cyclophosphamide,
doxorubicin, vincristine, etoposide, and prednisone supported with
G-CSF) followed by systemic CNS prophylaxis with one course of
high-dose methotrexate and one course of high-dose cytarabine
[18]. The original clinical study included 156 eligible patients.
Histological diagnosis was established from surgical or needle
biopsy of the pretreatment tumour tissue by local pathologists
according to current criteria of the World Health Organization
classification [19], and subsequently reviewed by expert hemato-
pathologists on a national basis. The patient selection for this
molecular study was based on availability of fresh frozen tissue
containing adequate material for DNA extraction and aGCH
(screening cohort; n = 51), and for RNA extraction and gene
expression profiling (n = 38). The infiltration of lymphoma cells in
the tissue was assessed from frozen tissue section using hematox-
ylin eosin and toluidine blue stainings. Formalin-fixed paraffin-
embedded (FFPE) tissue containing adequate material was used for
the preparation of TMAs (TMA cohort; n = 70).
To validate the findings, an independent series of 146 primary
DLBCL patients treated with chemoimmunotherapy at the
Helsinki University Central Hospital between 2001 and 2010
was used. The patients were treated with R-CHOP (n= 126), R-
CHOEP (n=11) or other regimen (n=9). The cases were selected
based on the availability of FFPE tissue and clinical information.
Samples
RNA and DNA were extracted with Qiaqen AllPrep DNA/
RNA/Protein Mini kit. CNAs were analysed from the DNA of 51
tumour samples hybridized onto Agilent Human (46) 180 K
CGH arrays. Tumour samples from 38 patients were eligible for
mRNA analyses using Affymetrix Human Exon 1.0 ST arrays. All
hybridizations were performed at the Biomedicum Genomics
(University of Helsinki) according to manufacturer’s instructions.
Hybridization protocols and raw expression microarray data are
available at ArrayExpress archive http://www.ebi.ac.uk/
arrayexpress/experiments/E-MEXP-3488 and http://www.ebi.
ac.uk/arrayexpress/experiments/E-MEXP-3463. All tissue sam-
ples were collected before treatment.
qRT-PCR
Expression of the COMMD1 (Hs04190004_m1) and XPO1
(Hs00418963_m1) genes were validated by quantitative real-time
polymerase chain reaction (qRT-PCR) using TaqMan Gene
Expression Assays (Assays-On-Demand, Applied Biosystems) and
the ABI Prism 7500 Fast Sequence Detection System (Applied
Biosystems) for 24 available tumour samples. Normalization for
the quantity of DNA was done by performing simultaneous qRT-
PCR for GAPDH (TaqMan Pre-Developed Assay Reagents,
Applied Biosystems). Each assay was determined by a comparative
cycle threshold method, using the arithmetic formula provided by
the manufacturer. All assays were performed in triplicate.
Subgroup Classification by Gene Expression Profiling
Samples involved in exon array analysis were divided into
germinal centre B-cell (GCB) and non-GCB subgroups by gene
expression profiling (GEP). Briefly, we utilized the log ratios of 44
genes from the gene expression panel by Wright et al. [20] and
agglomerative hierarchical clustering (complete linkage) to divide
samples into two subgroups. The IGHM gene was not on our array
and was subsequently dropped from the analysis. Following the
Wright classification [20], samples in one main branch of the
resulting cluster tree were categorized as GCB and samples in the
other branch as non-GCB DLBCLs. In addition, all samples were
classified into GCB and non-GCB phenotypes immunohistochem-
ically (IHC) according to Hans algorithm [21].
Immunohistochemical Analyses of COMMD1
IHC stainings were performed on FFPE tissue sections on TMA
slides containing 2–4 tissue cores/patient, with a core diameter of
1 mm (TMA cohort), or whole tissue sections (independent
validation cohort). After deparaffinization, heat-induced epitope
retrieval (121uC, 3 min), and blocking of endogenous peroxidase,
the slides were incubated with anti-COMMD1 antibody (1:200,
Sigma-Aldrich, Prestige Antibodies) at 4uC overnight. Staining
was completed with Vectastain ABC kit reagents (Vector
Laboratories) according to the manufacturer’s instructions, and
slides were counterstained with hematoxylin.
Integrative Genomic Profiling in DLBCL
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To score the stainings, COMMD1-positivity was evaluated
from one to three high-power fields (hpf; x630 magnification) with
the Leica DM LB bright-field microscope (Leica Microsystems
GmbH) and a camera attached to it (Olympus DP50, InStudio
1.0.1 Software). The most representative areas with intense
staining pattern were first selected with low magnification and
further digitized with hpf, resulting in microscopic images with
area size of 0.02 mm2. Images were subsequently scored using
computerized image analysis system [22]. All scorings were
performed blindly.
Quantitative image analyses were performed using Anduril
[22]. The colour space of each image was categorized to four
expected representative colour classes: Brown, blue, white and
background. The background class included faint brown and blue
colours considered to be unspecific staining. The colour values
were selected by pointing at 15 example colours for each class. All
images were subjugated to use the same class specification. Each
pixel was assigned to a class by finding the nearest example colour
value, and a final staining coverage calculated from the area of
each class present in each image.
Data Analysis
In copy number profiling the aCGH data were first normalized
with locally weighted scatterplot smoothing (LOWESS) normal-
ization (four iterations, 30% window) and the data were denoised
with circular binary segmentation (p,0.05, split undo= none)
[23]. The background noise level of copy number arrays was
estimated by calculating the median probe signal of all arrays. An
aberration was called significant if it was two standard deviations
apart from the median. We identified minimal common CNA
regions in which a CNA overlapped in 10% of the samples with
both transcriptome and copy number data, and subsequent
analysis were restricted to these regions. The Database of
Genomic Variants (DGV, version 10, Nov 2010) [24] was used
to determine locus specific copy number variants (CNVs). In short,
for each gene in our CNA regions, the number of overlapping
CNVs in the DGV according to genomic locus was counted.
Genes with more than 10 CNVs were excluded from the
subsequent analyses. Exon array expression data were normalized
and transformed to gene expression level data by the Multiple
Exon Array Preprocessing (MEAP) algorithm [25].
In order to find genes with a significant association of expression
and CNA, all genes in the expression data, which were located in a
minimal common CNA region, were first matched with their
respective segmented copy number values. The samples were split
into two groups based on their CNA status, separately for gains
and losses, and a signal-to-noise statistic on the expression of each
gene was calculated [26]. A p-value for each signal-to-noise score
was calculated with a permutation test. Gain or deletion was
associated with expression for genes that displayed up- or
downregulation in CNA samples but stable expression in non-
CNA samples (p,0.05). Moreover, only genes that exhibited CNA
in at least three patients were analysed.
A Chi square test was performed to evaluate the differences in
the frequency for the prognostic factors. Categorical data were
compared using the Fisher’s exact test (two-sided). Pearson
correlation coefficient was calculated to evaluate the correlation
between the expression values from microarray and qRT-PCR
analyses. All genes with altered copy number levels in at least five
samples were analysed for patient survival. Survival curves with
corresponding p-values were calculated using Kaplan-Meier
analysis with the log-rank test. Receiver operating characteristic
(ROC) curve analysis was used to determine the ideal cutoff values
for survival outcomes. Univariate analyses were performed
according to the Cox proportional hazards regression model.
The progression-free survival (PFS) was calculated as the period
between the dates of registration and lymphoma progression or
relapse. Otherwise, the patients were censored at the last date of
follow-up. Patients in remission were censored at the last date they
were known to be alive. Patients who died due to causes other than
lymphoma were censored at the date of death. Overall survival
(OS) was calculated as a period between registration date and date
of death. Surviving patients were censored at the last date they
were known to be alive. Lymphoma-specific OS was calculated as
a period between registration date and the date of death due to
lymphoma. P-values less than 0.05 were considered to indicate
statistical significance. Data analyses were done with the compu-
tational framework Anduril [22], which is designed for systematic
integration, analysis and result interpretation of large-scale
molecular data, and with IBM SPSS Statistics 20.0.
Results
Clinical Characteristics of the Screening Cohort
The baseline characteristics of the screening (aCGH) cohort of
51 patients treated in the NLG-LBC-04 protocol [18] are shown in
Table 1. Median age of the patients was 55 years (range, 20–65
years). The overall response rate (ORR; complete response (CR)+
partial response (PR)) in this study population was 98%. Median
follow-up of the patient cohort was 55 months (range 31–101
months), 15 patients had relapsed, three experienced CNS relapse
and 12 had died. Five of the deaths were not lymphoma-related.
Predicted 5-year PFS was 69%, lymphoma-specific OS 85%, and
OS 76%.
Gene Copy Number Aberrations
Genome-wide copy number analysis of 51 lymphoma samples
with aCGH revealed several gains and losses. All patients had at
least one abnormality with an average number of 17.569.8 CNAs
per patient. The most frequently ($10%) altered regions as well as
their frequencies and possible target genes are shown in Table 2.
Some samples exhibited narrower alterations than others, which
caused the small variation in the CNA frequencies. Of the
recurrent CNAs previously reported in DLBCL [27–30], gains in
3q, 7q22.1, and 19p13, and loss in 6q were observed in 9.8% of
the patients.
The association of CNAs with molecular subgroups is summa-
rized in Table S1 in File S1. Notably, GCB type DLBCL was
characterized by more frequent gain of 2p15 and 2p16.1 including
the well-known proto-oncogenes REL and BCL11A as compared to
non-GCB DLBCL (15–19% vs. 5%, p=ns). Instead, the most
frequently altered genomic regions in the non-GCB DLBCL
subgroup in comparison to GCB DLBCL patients were gains of
18q12.2 (20% vs. 4%, p=ns) and 18q23 (20% vs. 4–7%, p=ns),
and loss of 9p21.3 (30–35% vs. 7%, p=0.026). Of the other
genomic imbalances (,10% of all patients), only the gain of
18q21.2–33 in the non-GCB subgroup was significantly more
frequent when compared to GCB subgroup (20% vs. 0%,
p=0.027).
Copy Number Associated Gene Expression Changes
To identify genes with altered expression due to large genomic
aberrations, we combined the CNA and gene expression data
obtained from 38 patients for whom both data sets were available.
Our analysis showed that copy number gains and losses of 31
genes were associated with a simultaneous and significant increase
or decrease in gene expression. The majority (n=29) of the genes
were over-expressed due to copy number gains in chromosomes 2
Integrative Genomic Profiling in DLBCL
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(2p15 and 2p16.1) and 18 (18q21.2, 18q21.31–33, 18q23). In
contrast, two genes were suppressed and located in regions of copy
number losses at 9p21.3. The aforementioned CNA areas and
target genes are presented in more detail in Table S2 in File S1
and at http://csbi.ltdk.helsinki.fi/pub/lymphoma. As an example,
the patients with 2p15 amplification had elevated COMMD1
expression with a p-value and fdr ,0.001.
Prognostic Significance of Chromosomal Alterations
In the whole series of 51 patients with the aGCH data, we found
two chromosomal regions with genomic alterations associated with
PFS and lymphoma-specific OS. Patients with amplification in
chromosome 2p15 (n=6; 12% of all patients) had inferior PFS in
comparison to patients without this gain (p=0.010; Figure 1A). In
addition a non-significant difference towards poor lymphoma-
specific OS was observed (p=0.131; Figure 1B). Similarly, patients
with amplification in 18q12.2 (n=6) had worse PFS (p=0.044)
and lymphoma-specific OS (p,0.001) than patients without this
gain (Figures 1C and 1D). The survival associated gain in 2p15
contained the genes B3GNT2 (UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 2), FAM161A (family with sequence
similarity 161, member A), CCT4 (chaperonin containing TCP1
subunit 4), COMMD1 (copper metabolism (Murr1) domain
containing 1), and XPO1 (exportin 1), and the amplification was
associated with their over-expression (Figure 2). Association of
COMMD1 and XPO1 over-expression with 2p15 amplification was
further confirmed by qRT-PCR (Figure S1 in File S1). The
amplification in 18q12.2 contained the CELF4 gene but we found
Table 1. Patient characteristics in the screening cohort.
All n (%) 51 (100)
Gender Female 19 (37)
Male 32 (63)
Age Median (range) 55 (20–65)
,60 35 (69)
60–65 16 (31)
.65 0 (0)
Histology GCB 27 (53)
Non-GCB 20 (39)
Other/Unclassified 4 (8)
Performance status 0–1 33 (65)
2–3 18 (35)
B-symptoms 31 (61)
Elevated LDH 49 (96)
Stage I–II 1 (3)
III–IV 37 (97)
aaIPI 0 0 (0)
1 0 (0)
2 36 (71)
3 15 (29)
mRNA analysis 38 (75)
doi:10.1371/journal.pone.0091031.t001
Table 2. Genome-wide overview of recurrent gains and losses.
Band Gain Freq % Loss Freq % Position (Mb) Possible target genes
1q24.2 12 8 167.69–167.76 MPZL1
1q44 20 6 247.00–247.10 AHCTF1
2p16.1–p15 12 NA 60.68–63.27 BCL11A, PAPOLG, REL, PUS10, PEX13, KIAA1841, AHSA2, USP34,
XPO1, FAM161A, CCT4, COMMD1, B3GNT2, TMEM17, EHBP1
9p21.3 NA 14–18 21.80–22.01 MTAP, CDKN2A, C9orf53, CDKN2B
14q11.2 2 12 22.938–22.939 TRDV3
18q12.2 12 NA 34.82–35.15 CELF4
18q21.1 12 4 44.06–44.34 LOXHD1, ST8SIA5
18q23 12–16 4 77.62–77.71 KCNG2, PQLC1
20q11.22 16 NA 33.13–33.15 MAP1LC3A
doi:10.1371/journal.pone.0091031.t002
Integrative Genomic Profiling in DLBCL
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no correlation between the gain and CELF4 gene expression
(Figure 2).
Consistent with previous studies on lymphomas [27,28,31], we
identified REL and BCL11A located at 2p16.1, and BCL2 at
18q21.3 being among the genes, whose expression was linked with
copy number gains (Table S2 in File S1). CDKN2A and MTAP
genes, which have also been described in lymphomas, specifically
in the chemoresistant and ABC type DLBCLs [27,28,30,32,33]},
were in turn located in the regions of copy number losses at
9p21.3. However, these genomic alterations were not associated
with survival in our study population.
To further identify biomarker candidates located in the survival
associated 2p15 amplification locus, we performed survival
analysis for five genes whose expression values correlated with
amplification. Using gene expression values as continuous
variables in Cox univariate analyses, only COMMD1 expression
was identified to have prognostic impact on PFS (p=0.037). When
Kaplan-Meier analysis was performed, patients with high
COMMD1 expression had significantly inferior PFS as compared
to patients with low expression (5-year PFS 65% vs. 100%,
p=0.033; Figure 3A). Association of COMMD1 expression with
the survival was further validated using qRT-PCR and Cox
univariate analysis with continuous variables (p=0.009) and
Kaplan-Meier analysis with categorical data (p=0.031,
Figure 3B). In comparison, the expression of XPO1, another
selected gene for qRT-PCR validation, was not significantly
associated with survival (p=0.345). Correlation coefficients
between the expression arrays and qRT-PCR were 0.641 (p,
0.001) for COMMD1 and 0.494 (p=0.037) for XPO1.
COMMD1 Protein Expression is Associated with Outcome
Considering that our multi-level analysis revealed COMMD1 to
be amplified, over-expressed and survival associated gene in
DLBCL, we extended COMMD1 analyses to the protein level.
IHC stainings were performed on a TMA consisting of 70
lymphoma samples from the patients treated in the NLG-LBC-04
protocol (Table 3). Overall, intensity of COMMD1 positivity was
highly variable (Figure 4A–B). COMMD1 immunoreactivity was
primarily localized as perinuclear, granular, cytoplasmic pattern in
lymphoma cells (Figure 4B), but also in endothelial cells and
macrophages with more uniform cytoplasmic staining pattern.
The prognostic significance of COMMD1 expression and
correlation with mRNA data were assessed by computerized
image analysis of COMMD1 positivity in the tumour tissue. In the
univariate analysis the increasing COMMD1 positivity was an
adverse prognostic factor for PFS (p=0.003). The cutoff point for
survival outcomes was selected by ROC curve analysis, resulting in
Figure 1. Survival of DLBCL patients according to genomic aberrations. PFS (A and C) and lymphoma-associated OS (B and D) rates
according to indicated genomic aberration.
doi:10.1371/journal.pone.0091031.g001
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a staining coverage of 8.9% being the most discriminative value
(median 7.3%, range 0–24%), with an area under the curve (AUC)
value of 0.663 (95% CI 0.516–0.810, p=0.027). In Kaplan-Meier
analyses, the patients with high COMMD1 expression had a
significantly worse PFS and a trend towards adverse lymphoma
associated OS in comparison to the remaining patients with lower
COMMD1 expression (5-year PFS 47% vs. 79%, p=0.005
(Figure 4C) and 5-year OS 75% vs. 90%, p=0.081). According
to COMMD1 expression, the relative risk of relapse was 3.2 (95%
CI 1.361–7.584, p = 0.008) and death 2.825 (95% CI 0.837–9.536,
p = 0.094). In multivariate analysis with aaIPI, COMMD1
expression retained its prognostic value on PFS (RR 2.996; CI
1.210–7.418, p= 0.018). When clinical characteristics of the
patients were compared according to COMMD1 expression, no
differences in gender, subtype, age, LDH level or stage were
observed between the subgroups (Table 3). However, low
COMMD1 expression was associated with low performance
status.
We also examined prognostic impact on COMMD1 expression
according to molecular subtype, and found that a significant
adverse prognostic impact of COMMD1 expression was restricted
to the GCB subgroup (Fig. 4D; p= 0.029). The relative risk of
relapse according to COMMD1 expression within the GCB
subgroup was 3.434 (95% CI 1.056–11.164, p = 0.040). Overall,
immunohistochemically defined molecular subgroup was not
associated with survival.
In contrast to the results from genomic and transcriptomic
levels, no correlation was found between COMMD1 protein levels
and CNA or gene expression data (r = 0.236). The observation
suggests that post-transcriptional mechanisms may be involved in
the regulation of COMMD1 protein levels in DLBCL.
Figure 2. Expression of genes associated with amplifications in 2p15 and 18q12.2 locuses. Boxes contain expression values between the
25th and 75th percentile in the tumour subgroup. The extremes denoted by asterisks represent maximum and minimum expression values.
doi:10.1371/journal.pone.0091031.g002
Integrative Genomic Profiling in DLBCL
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COMMD1 Expression in an Independent DLBCL Series
In order to further validate the importance of COMMD1 in
DLBCL, we analysed the prognostic significance of COMMD1
expression in a larger independent cohort of 146 DLBCL patients
treated with chemoimmunotherapy (Table 3). Median age of the
whole cohort was 63 years (range, 16–84 years), median follow-up
64 months (range 20–133 months), predicted 5-year PFS 74%,
lymphoma-specific OS 79%, and OS 71%. While high IPI score
was a strong predictor for survival (p,0.001), immunohistochem-
ically defined molecular subgroup was not associated with
outcome.
The clinical features of the patients according to COMMD1
expression (low versus high, cut-off defined according to TMA
cohort) are summarized in Table 3. Accordingly, no differences
were observed between COMMD1 low and high subgroups. In
Kaplan-Meier analyses, PFS at five years for the patients with high
Figure 3. PFS according to COMMD1 expression. A. PFS according to exon array based COMMD1 expression values. B. PFS according to
quantitative PCR analysis based COMMD1 expression values. In both A and B, the ideal cutoff values have been calculated using ROC curve analyses.
In A the estimated area under the curve (AUC) was 0.717 (p= 0.063, 95% CI 0.531–0.903). In B the AUC was 0.759 (p= 0.062, 95% CI 0.468–1.000).
doi:10.1371/journal.pone.0091031.g003
Figure 4. COMMD1 protein expression and outcome. Representative examples of low (A) and high (B) expression levels of COMMD1 in FFPE
DLBCL tissue (original magnifications 1006, and 4006). C–D. Outcome according to COMMD1 expression in the trial specific TMA cohort. PFS in in the
whole TMA cohort (C) and in the GCB subgroup (D). E–F. Outcome according COMMD1 expression in the validation cohort. PFS in in the whole
validation cohort (E) and in the GCB subgroup (F). The cutoff point (staining coverage of 8.9%) for survival outcomes (COMMD1 low vs high) was
selected by the ROC curve analysis in the training set, and then applied also to validation cohort.
doi:10.1371/journal.pone.0091031.g004
Integrative Genomic Profiling in DLBCL
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COMMD1 expression was 64% compared with 79% for those
with lower expression levels (p=0.034; Figure 4E). When adjusted
for IPI, COMMD1 expression maintained its prognostic effect on
PFS (p=0.023). In addition, when adjusted for age (,60 vs. $60),
COMMD1 expression remained predictor for PFS (p=0.035).
According to COMMD1 expression, the relative risk or relapse
was 1.9 (95% CI 1.040–3.606, p=0.037). In multivariate analysis
with IPI, COMMD1 retained its prognostic value on PFS (RR 2.0;
95% CI 1.037–3.730, p=0.038).
Finally, when adjusted for molecular subgroups, COMMD1
expression was marginally predictive for PFS (p=0.066). When
COMMD1-related PFS was analysed separately for the patients in
different molecular subtypes, there was a non-significant difference
in PFS between COMMD1 high and low subgroups in the GCB
DLBCLs (Fig. 4F; p=NS). Collectively, the results in our two
independent cohorts provide evidence that COMMD1 is a novel
survival-associated marker in DLBCLs.
Discussion
Although the addition of rituximab to chemotherapy has
considerably improved the survival rates of DLBCL, the patients
with high IPI scores still have a poor prognosis. Here we have
studied genomic alterations and gene expression in freshly frozen
lymphoma tissue collected prospectively from patients included in
a Nordic phase II study for young high-risk DLBCL patients. With
this comprehensive approach we have identified copy number
gain at 2p15 driving COMMD1 mRNA upregulation with impact
on survival. The gain was more frequently seen in the GCB than
ABC DLBCLs. Furthermore, we have validated the results at the
protein level by IHC in the same patient cohort as well as in an
independent larger series. These data show that COMMD1 is a
novel biomarker candidate that may be useful in improving risk
stratification for DLBCL patients.
In a previous prospective study of poor prognosis DLBCL
patients treated uniformly with dose-escalated CHOP followed by
high-dose chemotherapy with autologous stem cell transplanta-
tion, the amplification of 2p16.1 was suggested to be associated
with poor treatment response [34]. Candidate genes mapped
within this amplification include proto-oncogenes REL and
BCL11A, with increased expression levels [31,35]. However, the
functional correlation of this amplification event has not been
illustrated [36]. Although REL and BCL11A expression levels were
integrated with chromosomal amplification in our cohort, they
were not associated with survival. Instead, we observed that the
increased copy number in region 2p15 was associated with adverse
PFS and lymphoma-specific OS. The region covers five genes,
CCT4, XPO1, COMMD1, FAM161A and B3GNT2, which are all
potentially important regulators of cellular growth. None of the
genes, however, have previously been associated with DLBCL
biology. While further investigation of the roles of these genes in
DLBCL pathogenesis is needed, our results demonstrate that
COMMD1 is a candidate genetic prognostic biomarker in DLBCL.
COMMD1 is a pleiotropic factor that participates in multiple
processes, including copper metabolism, sodium excretion,
inflammatory responses, and adaptation to hypoxia [37]. Recent
mechanistic studies have revealed that COMMD1 suppresses NF-
kB- and HIF-mediated gene expression [38,39]. COMMD1 is
underexpressed in some carcinomas, and low COMMD1 expres-
sion has been associated with inferior clinical outcome in patients
with endometrial cancer [39]. In lymphomas, the prognostic role
of COMMD1 has not previously been established. In the
Oncomine database [40] the expression of COMMD1 is increased
in lymphomas in comparison to other cancers [41]. Furthermore,
two independent studies showed that COMMD1 expression is
higher in DLBCLs than follicular lymphomas [41,42], whereas no
differences in the COMMD1 expression were observed between
molecular subtypes of DLBCL [9]. At the present time, it remains
unclear how COMMD1 is involved in a variety of seemingly
unrelated and even opposite cellular activities. However, in most
instances including lymphomas, the mechanism is likely via
protein-protein interactions and ubiquitination [39,43,44].
To confirm whether COMMD1 expression could be useful to
recognize DLBCLs with a more aggressive clinical course, we
studied COMMD1 protein expression by IHC, which is a method
that can be easily incorporated into a routine diagnostic approach.
The predictive value of COMMD1 positivity was first defined in a
training cohort of clinically high-risk DLBCL patients, and
subsequently confirmed in an independent, larger and more
heterogeneous DLBCL cohort. Thus, COMMD1 expression
seems to represent a potential novel prognostic marker preferen-
tially in the GCB type molecular subgroup.
Recently Monti and colleagues investigated gene expression and
copy number data in 168 DLBCL patients, with the focus on the
role of p53/cell cycle pathway in patient survival [28]. Interest-
ingly, even though they reported that the region harboring
COMMD1 is the second highest region in their cohort, and
COMMD1 among the top genes in the region (Table1S in their
publication [28]), they did not study its survival association.
Additionally, our findings are supported by reports showing
amplification of 2p15-p16 with the concordant elevated gene
expression in DLBCL [28,31,34,35]. These indicate that while
integration of copy number and expression data is known to be a
powerful approach to find driver genes, carefully selected,
homogenous patient cohort together with integrative analysis
can produce clear and important findings that may not be evident
in more heterogeneous cohorts.
Since CNA status was integrated with gene expression data,
only the genes, whose expression correlated with the CNAs were
identified. The results from the qRT-PCR also correlated with the
exon array data. However, we found no correlation between
COMMD1 protein and gene expression levels. The reason for this
difference is currently unknown but based on the literature
indicating a strong regulatory role for the processes downstream of
transcription [45,46], it is plausible to speculate that post-
transcriptional mechanisms may have a role in the regulation of
COMMD1 protein levels in DLBCL. The work demonstrating
that COMMD1 cellular levels are tightly controlled by ubiquitina-
tion [47] provides additional evidence that the regulatory level
may be posttranslational. Together with the CNA data the results
indicate that COMMD1 expression is regulated at multiple levels.
Amplification in 18q12.2 was found to be another significant
CNA associated with inferior outcome. The gain has not been
previously associated with survival in DLBCL, but its deletion has
been reported to correlate with poor outcome in colorectal
carcinoma. The CNA was found to harbour a single gene,
CELF4/CUGBP, coding for a member of a family of RNA binding
proteins playing an essential role in post-transcriptional gene
regulation. However, despite the gain in 18q12.2 locus we were
not able to demonstrate the over-expression of the CELF4 gene.
While more work is needed to establish the exact role of the
18q12.2 gain in DLBCL, our data supports the prognostic
importance of this region in DLBCL.
Consistent with previous studies [27,30,32,33], expression of
CDKN2A was associated with deletion of 9p21.3 in our patient
cohort, and especially in the non-GCB subtype. However, overall
incidence of the deletion was lower and no correlation with
survival was found. Considering that aCGH and exon arrays were
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not performed on purified tumour samples it is possible that the
presence of background material (tumour infiltrating non-malig-
nant cells) could to some extent dilute tumour specific genetic
alterations and explain a lower incidence of 9p21 deletions in our
material. However, a more likely explanation for the differences in
the results between different studies is that clinical and histopath-
ological features of the study populations are not identical. The
differences in the treatments may also contribute.
In conclusion, we have integrated copy number alteration and
transcriptomic data in a carefully chosen high-risk DLBCL patient
cohort to identify biological markers that could be used in risk
stratification. We found two profiles with increased copy number
of genes in chromosomes 2p15 and 18q12.2 that predicted a poor
outcome for a subgroup of DLBCL patients. Furthermore, we
identified a novel potential genetic driver event with prognostic
significance. Notably, the prognostic impact of COMMD1 on
survival was also observed at the protein level. The strengths of our
study are a prospectively collected and homogenously treated
study population, the availability of copy number, gene expression
and IHC data from the same patients, the possibility to correlate
the findings with clinical outcome, and validate the findings in an
independent cohort of DLBCL patients. Our results demonstrate
that it is possible to use relatively small but carefully designed
prospective cohorts as a hypothesis generating material to identify
a list of putative targets, and then validate and extend the major
results to the protein level. Taken together, the results presented
herein are promising and novel, and emphasize the importance of
integrated genetic information and multilevel analyses for both the
optimal use of existing combination therapies and the develop-
ment of novel treatments for DLBCL.
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